Technical Analysis for SUPN - Supernus Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 29.42 1.52% 0.44
SUPN closed up 1.52 percent on Friday, September 20, 2019, on 1.49 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Up
See historical SUPN trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
50 DMA Resistance Bearish 1.52%
Shooting Star Candlestick Bearish 1.52%

Older signals for SUPN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.
Health Pharmaceutical Pharmaceutical Industry Drug Discovery Clinical Trial Design Of Experiments Epilepsy Clinical Research Attention Deficit Hyperactivity Disorder Depression Clinical Trial Product Central Nervous System Diseases Neurology Treatment Of Central Nervous System Diseases Treatment Of Depression Treatment Of Epilepsy
Is SUPN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 51.38
52 Week Low 25.32
Average Volume 524,904
200-Day Moving Average 33.9669
50-Day Moving Average 29.3914
20-Day Moving Average 27.627
10-Day Moving Average 28.49
Average True Range 1.086
ADX 21.55
+DI 17.5787
-DI 13.0068
Chandelier Exit (Long, 3 ATRs ) 26.552
Chandelier Exit (Short, 3 ATRs ) 28.578
Upper Bollinger Band 29.7048
Lower Bollinger Band 25.5492
Percent B (%b) 0.93
BandWidth 15.041807
MACD Line 0.0495
MACD Signal Line -0.3009
MACD Histogram 0.3504
Fundamentals Value
Market Cap 1.49 Billion
Num Shares 50.7 Million
EPS 1.98
Price-to-Earnings (P/E) Ratio 14.86
Price-to-Sales 8.00
Price-to-Book 8.81
PEG Ratio 1.42
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.77
Resistance 3 (R3) 30.73 30.24 30.55
Resistance 2 (R2) 30.24 29.90 30.26 30.47
Resistance 1 (R1) 29.83 29.68 30.04 29.87 30.39
Pivot Point 29.34 29.34 29.44 29.36 29.34
Support 1 (S1) 28.93 29.00 29.14 28.97 28.45
Support 2 (S2) 28.44 28.78 28.46 28.37
Support 3 (S3) 28.03 28.44 28.30
Support 4 (S4) 28.07